Enanta Pharmaceuticals Inc (ENTA)

31.96
0.52 1.60
NASDAQ : Health Care
Prev Close 32.48
Open 32.52
Day Low/High 31.88 / 32.73
52 Wk Low/High 16.75 / 51.89
Volume 103.30K
Avg Volume 181.60K
Exchange NASDAQ
Shares Outstanding 19.08M
Market Cap 611.63M
EPS 1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Enanta Announces 99 Percent SVR12 Rate In Chronic HCV Patients With Compensated Cirrhosis Treated With AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen Of Glecaprevir/Pibrentasvir (G/P)

Enanta Announces 99 Percent SVR12 Rate In Chronic HCV Patients With Compensated Cirrhosis Treated With AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen Of Glecaprevir/Pibrentasvir (G/P)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that 99 percent...

AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate In Chronic Hepatitis C Patients With Compensated Cirrhosis

AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate In Chronic Hepatitis C Patients With Compensated Cirrhosis

- New data demonstrated high SVR(12) rates across compensated cirrhotic patients with genotype 1, 2, 4, 5 or 6 chronic hepatitis C virus (HCV) infection with 12 weeks of treatment(1)

Commit To Purchase Enanta Pharmaceuticals At $25, Earn 9.1% Annualized Using Options

Commit To Purchase Enanta Pharmaceuticals At $25, Earn 9.1% Annualized Using Options

Investors considering a purchase of Enanta Pharmaceuticals, Inc. stock, but tentative about paying the going market price of $30.83/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Enanta Announces New Preclinical Data On Its FXR Agonist EDP-305 For Non-Alcoholic Steatohepatitis (NASH) And Primary Biliary Cholangitis (PBC) At The International Liver Congress™ 2017

Enanta Announces New Preclinical Data On Its FXR Agonist EDP-305 For Non-Alcoholic Steatohepatitis (NASH) And Primary Biliary Cholangitis (PBC) At The International Liver Congress™ 2017

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new data from its lead...

Enanta Pharmaceuticals To Host Conference Call On May 8 At 4:30 P.m. ET To Discuss Financial Results For Its Fiscal Second Quarter Ended March 31, 2017

Enanta Pharmaceuticals To Host Conference Call On May 8 At 4:30 P.m. ET To Discuss Financial Results For Its Fiscal Second Quarter Ended March 31, 2017

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to...

Enanta Pharmaceuticals Announces Data Presentations At The International Liver Congress™ 2017

Enanta Pharmaceuticals Announces Data Presentations At The International Liver Congress™ 2017

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that several abstracts...

Enanta Pharmaceuticals To Present At The H.C. Wainwright 1st Annual NASH Investor Conference

Enanta Pharmaceuticals To Present At The H.C. Wainwright 1st Annual NASH Investor Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

Enanta Announces Japanese Ministry Of Health, Labour And Welfare Grants Priority Review For AbbVie's Investigational HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C

Enanta Announces Japanese Ministry Of Health, Labour And Welfare Grants Priority Review For AbbVie's Investigational HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that priority review...

AbbVie Granted Priority Review In Japan For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C

AbbVie Granted Priority Review In Japan For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C

- Priority review granted in Japan, following EMA accelerated assessment and U.S. FDA priority review designations in December 2016 and January 2017 respectively

Enanta Announces CHMP Grants Positive Opinion For An Eight-Week Treatment Option With AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) + EXVIERA® (dasabuvir Tablets) For Patients With Genotype 1b Chronic Hepatitis C

Enanta Announces CHMP Grants Positive Opinion For An Eight-Week Treatment Option With AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) + EXVIERA® (dasabuvir Tablets) For Patients With Genotype 1b Chronic Hepatitis C

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced today that the Committee for...

AbbVie Receives CHMP Positive Opinion For Eight-Week Treatment Option With VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) + EXVIERA® (dasabuvir Tablets) For Patients With Genotype 1b Chronic Hepatitis C

AbbVie Receives CHMP Positive Opinion For Eight-Week Treatment Option With VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) + EXVIERA® (dasabuvir Tablets) For Patients With Genotype 1b Chronic Hepatitis C

- CHMP opinion brings AbbVie one step closer to approval of an eight-week regimen of VIEKIRAX + EXVIERA for previously untreated genotype 1b (GT1b) chronic hepatitis C virus (HCV) patients with minimal to moderate fibrosis*

Oversold Conditions For Enanta Pharmaceuticals (ENTA)

Oversold Conditions For Enanta Pharmaceuticals (ENTA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal First Quarter Ended December 31, 2016

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal First Quarter Ended December 31, 2016

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for...

Enanta Pharmaceuticals To Present At Two Upcoming Investor Conferences

Enanta Pharmaceuticals To Present At Two Upcoming Investor Conferences

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

Enanta Announces U.S. FDA Grants Priority Review To AbbVie's Investigational HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

Enanta Announces U.S. FDA Grants Priority Review To AbbVie's Investigational HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the U.

U.S. FDA Grants Priority Review To AbbVie For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

U.S. FDA Grants Priority Review To AbbVie For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

- If approved, G/P will provide an eight week, once-daily, ribavirin-free cure* for HCV patients without cirrhosis across all major genotypes

Enanta Announces EMA Grants Accelerated Assessment, Validates Marketing Authorization Application For AbbVie's Investigational HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes (GT1-6) Of Chronic Hepatitis C

Enanta Announces EMA Grants Accelerated Assessment, Validates Marketing Authorization Application For AbbVie's Investigational HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes (GT1-6) Of Chronic Hepatitis C

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that AbbVie's...

European Medicines Agency Grants Accelerated Assessment, Validates Marketing Authorization Application For AbbVie's Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

European Medicines Agency Grants Accelerated Assessment, Validates Marketing Authorization Application For AbbVie's Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

- If approved, G/P may provide a shorter, eight week, once-daily, ribavirin-free treatment option for the majority of HCV patients without cirrhosis

Enanta Pharmaceuticals To Host Conference Call On February 8 At 4:30 P.m. ET To Discuss Financial Results For Its Fiscal First Quarter Ended December 31, 2016

Enanta Pharmaceuticals To Host Conference Call On February 8 At 4:30 P.m. ET To Discuss Financial Results For Its Fiscal First Quarter Ended December 31, 2016

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to...

Enanta Announces High SVR12 Rates Achieved In Genotype 1 Chronic HCV Infected Japanese Patients With Eight Weeks Of Treatment With AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen Of Glecaprevir/Pibrentasvir (G/P)

Enanta Announces High SVR12 Rates Achieved In Genotype 1 Chronic HCV Infected Japanese Patients With Eight Weeks Of Treatment With AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen Of Glecaprevir/Pibrentasvir (G/P)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced results from AbbVie's...

Eight Weeks Of Treatment With AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen Of Glecaprevir/Pibrentasvir (G/P) For Chronic Hepatitis C Achieved High SVR[12] Rates In Genotype 1 Japanese Patients

Eight Weeks Of Treatment With AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen Of Glecaprevir/Pibrentasvir (G/P) For Chronic Hepatitis C Achieved High SVR[12] Rates In Genotype 1 Japanese Patients

- 99 percent (n=105/106) of genotype 1 (GT1) chronic HCV-infected Japanese patients without cirrhosis achieved SVR[12] with 8 weeks of G/P

Commit To Purchase Enanta Pharmaceuticals At $32, Earn 17.5% Annualized Using Options

Commit To Purchase Enanta Pharmaceuticals At $32, Earn 17.5% Annualized Using Options

Investors considering a purchase of Enanta Pharmaceuticals, Inc. shares, but cautious about paying the going market price of $36.34/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Enanta Pharmaceuticals Announces Highlights Of Business Overview And Update On Its Research And Development Programs To Be Presented At The 35th Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals Announces Highlights Of Business Overview And Update On Its Research And Development Programs To Be Presented At The 35th Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the highlights of its...

FDA Grants Fast Track Designation To Enanta's FXR Agonist Candidate, EDP-305, For The Treatment Of NASH With Liver Fibrosis

FDA Grants Fast Track Designation To Enanta's FXR Agonist Candidate, EDP-305, For The Treatment Of NASH With Liver Fibrosis

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the U.

Enanta Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

Enanta Pharmaceuticals Announces AbbVie's Submission Of NDA For Investigational, Pan-Genotypic HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Genotypes 1 Through 6 Of Chronic Hepatitis C Virus (HCV)

Enanta Pharmaceuticals Announces AbbVie's Submission Of NDA For Investigational, Pan-Genotypic HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Genotypes 1 Through 6 Of Chronic Hepatitis C Virus (HCV)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that AbbVie has...

AbbVie Submits New Drug Application To U.S. FDA For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C

AbbVie Submits New Drug Application To U.S. FDA For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C

- If approved, G/P will provide an eight week once-daily, ribavirin-free treatment option for HCV patients without cirrhosis across all major genotypes

Enanta Pharmaceuticals Announces The Appointment Of Dr. Lesley Russell To Its Board Of Directors

Enanta Pharmaceuticals Announces The Appointment Of Dr. Lesley Russell To Its Board Of Directors

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of...